Exenatide: Uses, Interactions, Mechanism of Action | DrugBank ...
Exenatide is a human glucacon-like peptide-1(GLP-1) receptor agonist Label. By activating this receptor, insulin secretion is increased and glucagon secretion is decreased in a glucose dependant manner Label. Exenatide also slows gastric emptying and …
Exenatide - Wikipedia
Exenatide is a glucagon-like peptide-1 receptor agonist (GLP-1 receptor agonist) also known as incretin mimetics. [7] It works by increasing insulin release from the pancreas and decreases excessive glucagon release. [7] Exenatide was approved for medical use in …
Exenatide - StatPearls - NCBI Bookshelf - National Center for ...
2023年5月29日 · Exenatide is a GLP-1 receptor agonist released from the gut and acts to increase glucose-dependent insulin secretion from pancreatic beta cells, suppress glucagon secretion, delay gastric emptying, and reduce food intake. The binding of the drug to pancreatic GLP-1 receptors mediates these actions.
exenatide injection DESCRIPTION BYETTA® (exenatide) is a synthetic peptide that has incretin-mimetic actions and was originally identified in the lizard Heloderma suspectum. BYETTA enhances...
Exenatide: Dosage, Mechanism/Onset of Action, Half-Life ...
2020年2月9日 · Exenatide is an analog of the hormone incretin (glucagon-like peptide 1 or GLP-1) which increases glucose-dependent insulin secretion, decreases inappropriate glucagon secretion, increases B-cell growth/replication, slows gastric emptying, and decreases food intake.
Population pharmacokinetics of exenatide - PMC
Exenatide, a peptide that controls glucose in patients with type 2 diabetes, is eliminated with a half‐life of ~2.4 h, primarily via renal mechanisms. However, a nonrenal elimination pathway had been posited, based on preclinical experiments and a limited clinical study.
2017年11月6日 · Exenatide infusion attenuates postprandial hyperglycemia by decreasing. EGP (by ~50%) and by slowing gastric emptying. Diabetes Mellitus, Insulin Secretion, Glucagon, Gastric Emptying. endogenous (primarily hepatic) glucose production (EGP) are well documented (20). fasting hyperglycemia.